Drug Profile
Research programme: apoptosis inducers - Adamed
Alternative Names: ONCO-3CLALatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Adamed
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Solid-tumours in Poland
- 08 Jan 2014 Research programme: apoptosis inducers - Adamed is available for licensing as of 08 Jan 2014. http://www.adamed.com.pl
- 06 Jan 2014 Early research in Solid tumours in Poland (unspecified route)